RESPIRATORY & ALLERGY

Innovative Solutions for Respiratory & Allergy Clinical Trials

Avance Clinical leads the way in driving innovation in Respiratory & Allergy clinical research. Our significant expertise spans a wide spectrum of indications including COPD, Respiratory Distress Syndrome, Asthma, Idiopathic Pulmonary Fibrosis, and more. From tackling common conditions like the Common Cold to rare diseases such as Pulmonary Arterial Hypertension, our team is dedicated to advancing treatments that improve patient outcomes. Partner with us to experience cutting-edge methodologies and tailored solutions that accelerate the development of novel therapeutics in respiratory and allergy medicine.

GET IN TOUCH WITH OUR
CLINICAL TRIAL EXPERTS

Three decades of experience in biotech drug development

WHY BIOTECHS
CHOOSE
AVANCE CLINICAL

Avance Clinical’s global teams have a world-class reputation for delivering quality data that is accepted by all the international regulatory authorities including FDA and EMA.

The Avance Clinical Technology & Innovation unit invests heavily in industry-leading as well as emerging technology platforms that elevate quality, speed, and cost metrics for our biotech clients. As part of this technology focus, Avance Clinical also has certified in-house platform specialists including Medidata trained experts.

Avance Clinical is one of the very few mid-sized global CROs with an in-house Scientific and Regulatory Affairs team delivering cross functional streamlined processes, and rapid and cost saving solutions.

Avance Clinical’s Australian operations can deliver Site Initiation Visit (SIV) and Study Start in 5 – 6 weeks. No IND is required. Indeed, more than 280 Phase III global trials conducted their Phase I in Australia. The 43.5% clinical trial rebate program can also extend to multi-regional later phases.